 |
 |
 |
 |
 |
 |
 |
 |
Press ReleaseMicro Laboratories Product Found to Reduce Withdrawal Symptoms During Quitting Smoking Clinical TrialsJOHNSTON, RI, Feb. 25, 2003 -- Micro Laboratories, Inc. (OTC Bulletin Board: MLAR - BERLIN: MIA) announced results of a study performed by Bruce Becker, MD, Beth Bock, PhD, and Rosa Carmona-Barros, MS of The Centers for Behavioral & Preventive Medicine, The Miriam Hospital, Rhode Island Hospital, and Brown Medical School. The study found that one of Micro Laboratories products help to reduce withdrawal symptoms during quitting smoking clinical trials.Dr. Becker presented a paper entitled, "St. John's Wort Oral Spray Reduces Withdrawal Symptoms During Quitting Smoking" on February 22 at the Society for Research on Nicotine & Tobacco's 9th Annual Scientific Session being held at the Sheraton New Orleans Hotel. (www.srnt.org) The study tested the effect of St. John's Wort, a natural herbal preparation, on smoking withdrawal symptoms. St. John's Wort was delivered to the patient in a unique oral spray formulation which could be used multiple times per day by the subject, mirroring the subject's pattern of cigarette smoking. St. John's Wort decreased subject's anxiety, sleepiness, and restlessness during the first few days after quitting and their cravings for cigarettes and irritability throughout the 2 week study period. Robert Thistle, CEO of Micro Laboratories, stated, "We are pleased that this study affirms our belief that oral spray delivery of certain medications can provide a very real benefit. This expands the validity of our spray vitamin products." About Micro Laboratories, Inc. Micro Laboratories, Inc. is a specialist in the design and manufacture of Micro Spray(R) vitamins, anti-depressant and oral breath sprays. Micro Spray(R) products also have a patented formula for the prevention of halitosis and tooth decay. Micro Spray(R) is fully developed and offers a 90% absorption rate higher than products administered by pill. The Micro Spray delivery system is sprayed directly under the tongue or the inside of the check in a fine mist. Micro Spray(R) is absorbed into the bloodstream and assimilated throughout the body. This press release includes forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Inherent risks and uncertainties could cause actual results to differ materially from the forward-looking statements. Such risks and uncertainties are described in the periodic reports the Company files with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release. For more information on Micro Laboratories or to purchase Micro Spray products, please contact: Robert Thistle, CEO of Micro Laboratories, Inc. at (800) 555-1276. A multimedia presentation about the company and its line of products can be viewed at: http://www.e3dmarketing.com/mlar For press inquiries or to arrange interviews with Dr. Becker, please contact Robert Schechter of Equity Communications at 212-499-6809 or schechter_robert@hotmail.com. |
 Subscribe and receive targeted press release announcements. Choose from several categories. Sign up today!  Media Searches Reference Tools Journalism Sites Public Relations PR Bookstore Organizations/Assns. Careers |